EMA Authorised: Vedrop (tocofersolan) — Recordati Rare Diseases

View source ↗

Summary

The EMA has authorised Vedrop (tocofersolan) for the treatment of cholestasis-associated vitamin E deficiency under the marketing authorisation holder Recordati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis
• Vitamin Deficiency

Drugs mentioned

• Vedrop (tocofersolan)

Snippet

Status: Authorised. Therapeutic area: Cholestasis;Vitamin E Deficiency. MAH: Recordati Rare Diseases. Decision date: 10/12/2024